UY33230A - Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno - Google Patents
Aminotiazolonas como moduladores del receptor alfa relacionados con estrógenoInfo
- Publication number
- UY33230A UY33230A UY0001033230A UY33230A UY33230A UY 33230 A UY33230 A UY 33230A UY 0001033230 A UY0001033230 A UY 0001033230A UY 33230 A UY33230 A UY 33230A UY 33230 A UY33230 A UY 33230A
- Authority
- UY
- Uruguay
- Prior art keywords
- modulators
- alpha
- estrogen
- aminotiazolonas
- alfa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con nuevos compuestos de la Fórmula (I), métodos para preparar compuestos, composiciones, intermedios y derivados de estos y para el tratamiento de condiciones tales como, el cáncer, la artritis, la enfermedad inflamatoria de las vías respiratorias y trastornos metabólicos. Más particularmente, los compuestos de la presente invención son moduladores de los receptores de estrógeno alfa (ERR-a(alfa)) útiles para el tratamiento, mejorar o inhibir la progresión de estados de enfermedad, trastornos y condiciones mediadas por la actividad de ERR-a (alfa).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30517710P | 2010-02-17 | 2010-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33230A true UY33230A (es) | 2011-08-31 |
Family
ID=43920677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033230A UY33230A (es) | 2010-02-17 | 2011-02-17 | Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno |
Country Status (14)
Country | Link |
---|---|
US (1) | US8426604B2 (es) |
EP (1) | EP2536716B1 (es) |
JP (1) | JP2013519729A (es) |
KR (1) | KR20120133383A (es) |
CN (1) | CN102869660A (es) |
AR (1) | AR080206A1 (es) |
AU (1) | AU2011218268A1 (es) |
BR (1) | BR112012020604A2 (es) |
CA (1) | CA2789753A1 (es) |
MX (1) | MX2012009528A (es) |
RU (1) | RU2012139459A (es) |
TW (1) | TW201130831A (es) |
UY (1) | UY33230A (es) |
WO (1) | WO2011103130A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051632A1 (ja) * | 2011-10-04 | 2013-04-11 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
US10660882B2 (en) | 2012-03-26 | 2020-05-26 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
EP3632428A1 (en) | 2013-09-25 | 2020-04-08 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for use in the prophylactic or therapeutic treatment of giant cell tumors occurring in bone and soft tissue or of chondrosarcoma |
TW201811752A (zh) * | 2016-09-06 | 2018-04-01 | 比利時商健生藥品公司 | 用作升糖素受體拮抗劑之吲唑衍生物 |
CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2138346T3 (es) * | 1995-06-02 | 2000-01-01 | Sanofi Synthelabo | Derivados de 5-(hidroximetil)oxazolidin-2-ona. |
AU5348098A (en) | 1996-12-17 | 1998-07-15 | Quadrant Holdings Cambridge Limited | Melanocortins |
BRPI0513367A (pt) * | 2004-07-14 | 2008-05-06 | Janssen Pharmaceutica Nv | arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio |
EP1805154A4 (en) * | 2004-10-22 | 2009-11-25 | Exelixis Inc | PHARMACEUTICAL COMPOSITIONS |
JP2010520308A (ja) * | 2007-03-07 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | エストロゲン関連受容体−アルファモジュレーターとしての置換フェノキシアミノチアゾロン |
-
2011
- 2011-02-16 WO PCT/US2011/024999 patent/WO2011103130A1/en active Application Filing
- 2011-02-16 JP JP2012553980A patent/JP2013519729A/ja not_active Withdrawn
- 2011-02-16 AU AU2011218268A patent/AU2011218268A1/en not_active Abandoned
- 2011-02-16 EP EP11705404.9A patent/EP2536716B1/en active Active
- 2011-02-16 CN CN2011800194232A patent/CN102869660A/zh active Pending
- 2011-02-16 CA CA2789753A patent/CA2789753A1/en not_active Abandoned
- 2011-02-16 KR KR1020127023756A patent/KR20120133383A/ko not_active Application Discontinuation
- 2011-02-16 BR BR112012020604A patent/BR112012020604A2/pt not_active IP Right Cessation
- 2011-02-16 TW TW100105005A patent/TW201130831A/zh unknown
- 2011-02-16 MX MX2012009528A patent/MX2012009528A/es not_active Application Discontinuation
- 2011-02-16 US US13/028,266 patent/US8426604B2/en active Active
- 2011-02-16 RU RU2012139459/04A patent/RU2012139459A/ru not_active Application Discontinuation
- 2011-02-17 UY UY0001033230A patent/UY33230A/es unknown
- 2011-02-17 AR ARP110100487A patent/AR080206A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112012020604A2 (pt) | 2019-09-24 |
JP2013519729A (ja) | 2013-05-30 |
TW201130831A (en) | 2011-09-16 |
KR20120133383A (ko) | 2012-12-10 |
EP2536716B1 (en) | 2014-05-21 |
CN102869660A (zh) | 2013-01-09 |
WO2011103130A1 (en) | 2011-08-25 |
EP2536716A1 (en) | 2012-12-26 |
RU2012139459A (ru) | 2014-03-27 |
MX2012009528A (es) | 2013-01-14 |
CA2789753A1 (en) | 2011-08-25 |
AR080206A1 (es) | 2012-03-21 |
US20110200586A1 (en) | 2011-08-18 |
US8426604B2 (en) | 2013-04-23 |
AU2011218268A1 (en) | 2012-09-06 |
WO2011103130A8 (en) | 2012-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33231A (es) | Aminotiazolonas como moduladores de los receptores de estrógenos alfa | |
CO2017013229A2 (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
GT201500138A (es) | Novedososo derivados de bencimidazol como antagonistas de ep4 | |
PE20151141A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
CU20140055A7 (es) | Procedimiento de preparación de 5- fluoro- 1h-pirazolopiridinas sustituidas | |
CO7141404A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
CO7141403A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
EA201692412A1 (ru) | Синтез полициклических карбамоилпиридоновых соединений | |
GT201200201A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
CU20130040A7 (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
DOP2010000270A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
CO6721019A2 (es) | Quinazolincarboxamida azetidinas | |
CO6480975A2 (es) | Mimetico de smac | |
UY33118A (es) | Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
CL2017000818A1 (es) | Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii | |
CO6410257A2 (es) | Herbicidas novedosos | |
CU24402B1 (es) | 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer | |
CU20140103A7 (es) | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio | |
BR112014014939A2 (pt) | composição de tratamento de sementes | |
CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
ECSP11010867A (es) | Compuestos novedosos de fenilamino-isonicotinamida | |
UY33230A (es) | Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno |